Generic drugs

Shares of Endo International plc (NASDAQ: ENDP) traded as high as $6.94 Monday morning, but gave up some of the gains by the afternoon. The stock was still higher by more than 5 percent in reaction to the company's preliminary third-quarter results. Endo said on Monday it expects to report...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) were under heavy selling pressure Wednesday morning after the U.S. Food and Drug Administration granted approval for a rival product. The FDA granted approval to Mylan N.V. (NASDAQ: MYL) to sell a generic version of Teva's Copaxone...

Shares of Mylan N.V. (NASDAQ: MYL) traded higher by more than 13 percent Wednesday morning after the U.S. Food and Drug Administration granted approval for the company's generic version of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s Copaxone. Copaxone, a therapy that is intended...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) said Tuesday it has agreed to sell its Paragard IUD product to Cooper Companies Inc (NYSE: COO) in a $1.1 billion cash deal. Teva also confirmed it will continue divesting the remaining assets it holds within the women's health portfolio along...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) were trading higher by more than 11 percent early Monday morning after the company named Kare Schultz as its new CEO after a seven-month search period. Schultz brings decades of experience in the pharmaceutical industry and most...

Analysts at Argus no longer hold a bullish view on Mylan N.V. (NASDAQ: MYL) after the company cut its full-year guidance and cautioned that its earnings per share will decline in 2017. The firm's Jasper Hellweg downgraded Mylan's stock rating from Buy to Hold as the stock is fairly valued at its...

Based on the nearly 25-percent decline in Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock price on Thursday, some investors and analysts have legitimate concerns over the company's earnings report and outlook. Among those on Wall Street who share this concern include...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s earnings report brought mostly bad news for investors, which resulted in an 18-percent plunge in the stock Thursday morning. But not all analysts are ready to throw in the towel, as Credit Suisse's Vamil Divan maintains an Outperform...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), the troubled Israel-based generic and specialty medicines developer, confirmed with Bloomberg a plan to lower expenses and better manage its debt. A Bloomberg report cited Israeli-based news sources Calcalist, which initially reported Teva...

Lannett Company, Inc. (NYSE: LCI) was trading lower by more than 5 percent Tuesday after Citron Research slammed the distributor of generic drugs in a new report. According to Citron, Lannett will become the first pharmaceutical company to go bankrupt and its equity is worth $13 to $15 a share...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) hit a new 52-week low of $37.25 on Tuesday after the company reported its third-quarter results and provided a concerning outlook for the full year given some concerns over its specialty drugs. The stock rebounded slightly on Wednesday...

Express Scripts Holding Company (NASDAQ: ESRX), the largest pharmacy benefit management organization in the U.S., announced on Friday it has decided to exclude Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s Glumetza from its formulary. Express Scripts noted that throughout Valeant...